Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q1 2019 (← Previous) (Next →)

Filing Date: Apr 5, 2019

Total Value: $303.6B (100.0% shares, 0.0% debt)

Holdings (9)

CRSP CRISPR Therapeutics AG 50.0%

Value $151.8B Shares 4,248,888 Est. Cost $40.26 Unrealized -14.1%

VCYT Veracyte, Inc. 29.8%

Value $90.48B Shares 3,616,221 Est. Cost $11.03 Unrealized +73.2%

— Audentes Therapeutics, Inc. 10.3%

Value $31.34B Shares 803,106 Est. Cost $17810.00 Unrealized —

— CymaBay Therapeutics, Inc. 4.8%

Value $14.44B Shares 1,084,696 Est. Cost $9871.60 Unrealized —

OCUL Ocular Therapeutix, Inc. 2.9%

Value $8.795B Shares 2,215,384 Est. Cost $20.09 Unrealized -80.0%

— Second Sight Medical Products, Inc. 1.2%

Value $3.572B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— Clovis Oncology, Inc. 0.8%

Value $2.528B Shares 101,855 Est. Cost $56000.00 Unrealized —

— Achaogen, Inc. 0.2%

Value $585M Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— OpGen, Inc. 0.0%

Value $61.71M Shares 102,167 Est. Cost $1780.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	4,248,888	$151.8B	50.0%	$40.26	-14.1%	Common Stock	H17182108
VCYT	Veracyte, Inc.	3,616,221	$90.48B	29.8%	$11.03	+73.2%	Common Stock	92337F107
—	Audentes Therapeutics, Inc.	803,106	$31.34B	10.3%	$17810.00	—	Common Stock	05070R104
—	CymaBay Therapeutics, Inc.	1,084,696	$14.44B	4.8%	$9871.60	—	Common Stock	23257D103
OCUL	Ocular Therapeutix, Inc.	2,215,384	$8.795B	2.9%	$20.09	-80.0%	Common Stock	67576A100
—	Second Sight Medical Products, Inc.	4,492,975	$3.572B	1.2%	$1210.00	—	Common Stock	81362J100
—	Clovis Oncology, Inc.	101,855	$2.528B	0.8%	$56000.00	—	Common Stock	189464100
—	Achaogen, Inc.	1,281,152	$585M	0.2%	$13050.00	—	Common Stock	004449104
—	OpGen, Inc.	102,167	$61.71M	0.0%	$1780.00	—	Common Stock	68373L109